Sotyktu

crown royalty king queen win
Biotech

J&J's IL-23 drug defeats Sotyktu in phase 3 psoriasis trial

After being touted as a rival to BMS’ reigning psoriasis med Sotyktu for months, J&J’s IL-23 drug looks like it has a shot at taking the crown.
James Waldron Sep 17, 2025 9:45am
scrabble tiles spelling out psoriasis

J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu

Mar 10, 2025 7:30am
decision path change of plans arrows business decision

BMS backs out of Dupixent fight, axing asset despite phase 3 win

Feb 7, 2025 6:26am
Graphic image of the letters IPO in white in front of a yellow background

Alumis plans IPO to fund TYK2 inhibitor through phase 3 trials

Jun 10, 2024 8:35am
Takeda

How Takeda beat the rest of the industry to snag Nimbus' TYK2

Jan 11, 2024 10:30am
photo of a money printer printing out seven rows of 100 bills

Nimbus tacks on $210M as investors swat away IRA concerns

Sep 6, 2023 7:00am